Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy
Journal article
Tse, G. 2022. Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy. European Journal of Clinical Investigation.
Authors | Tse, G. |
---|---|
Abstract | Androgen deprivation therapy (ADT), which pharmacologically or surgically suppresses androgen activity, is a key treatment for prostate cancer (PCa).1 However, it is associated with increased cardiovascular risks, including elevated risks of cardiovascular mortality, myocardial infarction and stroke.2, 3 Nonetheless, prior studies have focussed on the first occurrence of adverse cardiovascular events,2, 4, 5 and the burden of cardiovascular hospitalizations in patients with PCa receiving ADT has remained unexplored. Similarly, the long-term burden of cardiovascular mortality amongst ADT users has been underexplored.6, 7 Given the adverse cardiovascular effects of ADT, it is important to better understand the long-term burden of cardiovascular mortality and hospitalizations in these patients. Henceforth, this study aimed to describe the long-term burden of cardiovascular mortality and hospitalizations in patients with PCa receiving ADT. |
Keywords | Androgen deprivation therapy; Cardio-oncology; Epidemiology; Prostate cancer |
Year | 2022 |
Journal | European Journal of Clinical Investigation |
Publisher | Wiley |
ISSN | 0014-2972 |
1365-2362 | |
Official URL | https://onlinelibrary.wiley.com/doi/10.1111/eci.13932 |
Publication dates | |
Online | 05 Dec 2022 |
Publication process dates | |
Accepted | 03 Dec 2022 |
Deposited | 15 May 2023 |
Publisher's version | License |
Output status | Published |
https://repository.canterbury.ac.uk/item/94951/long-term-cardiovascular-burden-in-prostate-cancer-patients-receiving-androgen-deprivation-therapy
Download files
Publisher's version
56
total views21
total downloads0
views this month0
downloads this month